Recordati S.p.a. · MIL:REC
Recordati — Goldman Sachs 29th Annual Global Healthcare Conference (June 2008)
19 slides from Recordati's conference presentation, Jun 10, 2008
Slide 1: A growing specialty pharmaceuticals company
Goldman Sachs 29th Annual Global Healthcare Conference Laguna Niguel, California, 10 June 2008 A growing specialty pharmaceuticals company
Slide 2: Company profile
Company profile ¾ A fully integrated pharmaceutical company listed on the Italian Stock Exchange since 1984 ¾ Original research focused on cardiovascular and urological fields ¾ A European company - marketing operations in France, Germany, Greece, Ireland, Italy, Portugal, Russia & C.I.S., Spain and
Slide 3: Breakdown of pharmaceutical revenue
Breakdown of pharmaceutical revenue UK Other European Spain 2% countries 0.7% Other international Portugal 4% sales 20% 7% Germany % of pharmaceutical 7% Orphan Europe revenue 6% Zanidip®/Zanipress® (lercanidipine/ 31% lercanidipine+enalapril) France 21% Elopram® /Entact® 6% Italy 33% (citalopram/es
Slide 4: ZANIDIP (lercanidipine)
ZANIDIP® (lercanidipine) ¾ Latest generation calcium-channel blocker. Lercanidipine as a % of all Lipophilic dihydropyridine. calcium channel blockers ¾ Natural once a day. Potent, long-lasting vasodilatory activity. Highly vasoselective with Bubble size represents $ market value of CCB’s gradual on
Slide 5: Orphan Europe
Orphan Europe ¾ Recordati completed the acquisition of Orphan Europe, a European pharmaceutical company dedicated to treatments for rare diseases, in December 2007 ¾ Orphan Europe operates in an untapped niche market. It has a well balanced, cash generating portfolio of 9 products with strong growth
Slide 6: R&D pipeline
R&D pipeline NAME ORIGINATOR INDICATION DEVELOPMENT STATUS Launched in the RMS (Germany) Zanipress®/Zanitek® Recordati Hypertension (lercanidipine+enalapril) MRP completed rupatadine Uriach Rhinitis, allergic, seasonal / perennial urticaria Approved fentanyl patch Lavipharm Moderate to severe chroni
Slide 7: Lercanidipine fixed combinations
Lercanidipine fixed combinations ¾ Fixed combinations will play a significant role in the future hypertension market ¾ New aggressive targets for blood pressure control. Combination of drugs needed for most patients ¾ Increased patient compliance ¾ Large clinical outcome trials show that cardiovascu
Slide 8: Silodosin
Silodosin ¾ Selective alpha-1A receptor antagonist indicated for the symptomatic treatment of benign prostatic hyperplasia ¾ Benign prostatic hyperplasia increasing in frequency due to the progressive ageing of the population ¾ Originator: Kissei ¾ Market of reference: class G4C European sales, appr
Slide 9: New developments for Lower Urinary Tract Symptoms (LUTS) and incontinence
New developments for the Lower Urinary Tract Symptoms (LUTS) and incontinence ¾ Irritative symptoms of the lower urinary tract (mainly urgency and frequency with or without incontinence) are frequent, mainly in women and the elderly. This condition, known as Overactive Bladder (OAB) is either idiopa
Slide 10: R&D pipeline – drugs for rare diseases
R&D pipeline – drugs for rare diseases NAME ORIGINATOR INDICATION DEVELOPMENT STATUS Orphan Europe Approved in EU Carbaglu® NAGS deficiency (Recordati) Filed in U.S. Orphan Europe Carbaglu® Organic acidemias Pre-registration in EU (Recordati) Orphan Europe Vitamin E deficiency in cystic fibrosis and
Slide 11: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Carbaglu® (carglumic acid), a drug developed by Orphan Europe for the treatment of NAGS deficiency, approved in the EU in 2003 and filed recently for approval with the FDA. Carbaglu® is also in pre-registration phase in Europe for additional indications in or
Slide 12: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Stanate® (stannsoporfin) Inhibits the production of bilirubin in cases of hyperbilirubinemia of different origin. Originated by Rockefeller University, is under development by InfaCare for the treatment of neonatal hyperbilirubinemia (jaundice). ¾ Severe hype
Slide 13: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Cystagon® (cysteamine bitartrate), a drug indicated for the treatment of nephropathic cystinosis, is being studied for a new and promising unrelated indication. ¾ Cystadrops® (cysteamine chlorhydrate), are eye drops developed for “ocular cystinosis” which can
Slide 14: First quarter 2008 Highlights
First quarter 2008 Highlights ¾ Revenue € 171.9 million, up 5.2%, international sales grow by 9.3% ¾ EBIT € 38.1 million, up 2.9% ¾ Net income € 25.3 million, up 7.4% ¾ Acquisition of FIC and FIC Médical, our distribution arm in Russia and other C.I.S. countries ¾ MRP for the approval in the EU of t
Slide 15: First quarter 2008 results
First quarter 2008 results (million Euro) 1Q 2008 1Q 2007 Change % Revenue 171.9 163.4 5.2 Gross Profit 116.1 109.0 6.5 as % of revenue 67.6% 66.7% SG&A Expenses 63.4 58.8 7.8 as % of revenue 36.9% 36.0% R&D Expenses 13.4 13.0 3.2 as % of revenue 7.8% 7.9% Other Income (Expense), net (1.2) (0.1) n.s
Slide 16: Full year 2007 results
Full year 2007 results (million Euro) 2007 2006 2005 2004 2003 Revenue 628.4 576.2 576.1 488.3 487.5 Gross Profit 422.1 384.2 375.5 309.0 287.8 as % of revenue 67.2% 66.7% 65.2% 63.3% 59.0% SG&A Expenses 236.0 218.3 217.6 177.8 169.2 as % of revenue 37.6% 37.9% 37.8% 36.4% 34.7% R&D Expenses 49.1 45
Slide 17: Net financial position
Net financial position (million Euro) 31 Mar 2008 31 Dec 2007 Change Cash and short-term financial 115.1 89.4 25.8 investments Bank overdrafts and short-term (102.5) (98.8) (3.7) loans Loans – due within one year (2.7) (2.9) 0.2 Loans – due after one year (84.1) (84.8) 0.7 NET FINANCIAL POSITION (74
Slide 18: Growth strategy
Growth strategy ¾ Develop our direct presence in Eastern Europe ¾ Reinforce our R&D pipeline ¾ Growing strategic interest in specialized therapies: development of Stanate®, development of new drugs for rare diseases ¾ Reinforce our presence in Germany, Spain and the UK through selective company and/
Slide 19: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan
Recordati — Goldman Sachs 29th Annual Global Healthcare Conference (June 2008) on 6ix